Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 6/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | TACR1 | P25103 | 3/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523231 | 1.00 | CASP1 (0.63) | CASP1HRH4TACR1TGM2CASP3 | |
| SCHEMBL10976664 | 1.00 | CASP1 (0.63) | CASP1HRH4TACR1TGM2CASP3 | |
| SCHEMBL7277023 | 1.00 | CASP1 (0.63) | CASP1HRH4TACR1TGM2CASP3 | |
| SCHEMBL29523440 | 1.00 | CASP1 (0.63) | CASP1HRH4TACR1TGM2CASP3 | |
| SCHEMBL3723146 | 0.91 | CASP1 (0.66) | CASP1HRH4TGM2CASP3MME | |
| SCHEMBL6487616 | 0.89 | CASP1 (0.60) | CASP1HRH4TACR1TGM2CASP3 | |
| SCHEMBL19586938 | 0.88 | HRH4 (0.58) | CASP1HRH4TACR1TGM2MME | |
| SCHEMBL19586939 | 0.88 | HRH4 (0.58) | CASP1HRH4TACR1TGM2MME | |
| SCHEMBL19606065 | 0.87 | CASP1 (0.58) | CASP1HRH4TACR1CASP3MME | |
| SCHEMBL19586943 | 0.87 | REN (0.62) | CASP3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3253775-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5716979-A | NONPEPTIDES, UNIQUE IN ALKYLATION/SUBSTITUTION PATTERN ALONG THEIR BACKBONE, USEFUL FOR TREATING DISORDERS SUCH AS RESPIRATORY, INFLAMMATORY, GASTROINTESTINAL, OPHTHALMIC, ALLERGIES, PAIN, VASCULAR, MIGRANE, ARTHRITIS AND BRAIN | WARNER-LAMBERT COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5594022-A | CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | CASP1 108/4885HRH4 201/4885TACR1 1179/4885 |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | CASP1 78/4885HRH4 2583/4885TACR1 2335/4885 |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | CASP1 101/4885HRH4 3895/4885TACR1 3329/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | CASP1 67/4885HRH4 2625/4885TACR1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.